Mesenchymal Stem Cells Therapy in critical COVID-19 patient: a case report

Authors

  • Novi Sukirto Ahmad Dahlan University
  • Zainul Arifin Internal Medicine Department, PKU Muhammadiyah Bantul Hospital
  • Sumardi Sumardi Pulmonology – Internal Medicine Department, Faculty of Medicine, Public Health and Nursing Gadjah Mada University
  • Barkah Purwanto Ahmad Dahlan University
  • Auliya Azisah Mansur Ahmad Dahlan University
  • Naila Sistharani Ahmad Dahlan University

DOI:

https://doi.org/10.12928/admj.v3i1.6460

Keywords:

ARDS; MODS; Stem Cell; cytokine storm; Natural Killer

Abstract

COVID-19 pneumonia with critical symptoms causes acute respiratory distress syndrome (ARDS) and multiple organ dysfunction syndromes (MODS) which can be severe complications until death. One therapy for Covid-19 critical was to suppress the effects of cytokine storms, which was administered by Mesenchymal Stem Cells therapy. In this case, we will report a case of COVID-19 with a critical patient that was given MSC therapy there were good outcomes in this case which were improvement of the clinical symptoms and prevent death.

 

ABSTRAK

Pneumonia COVID-19 dengan gejala kritis menyebabkan sindrom gangguan pernapasan akut (ARDS) dan sindrom disfungsi organ multipel (MODS) yang dapat menjadi komplikasi berat hingga kematian. Salah satu terapi kritis Covid-19 adalah menekan efek badai sitokin, yang dilakukan dengan terapi Sel Punca Mesenkim. Dalam kasus ini, kami akan melaporkan kasus COVID-19 dengan pasien kritis yang diberikan terapi MSC ada hasil yang baik dalam kasus ini yaitu perbaikan gejala klinis dan mencegah kematian

References

Pathophysiology, Transmission, Diagnosis, and Treatment of Coronavirus Disease 2019 (COVID-19) : A Review W. Joost Wiersinga, MD, PhD; Andrew Rhodes, MD, PhD; Allen C. Cheng, MD, PhD;Sharon J. Peacock, PhD; Hallie C. Prescott, MD, MSc. JAMA : 2020

Cytokine Storm in COVID-19: An Overview, Mechanism,ovid 19 Treatment Strategies, and Stem Cell Therapy Perspective. Nuriza Ulul Azmi1*, Meidi Utami Puteri2, Donny Lukmanto. Pharmaceutical Sciences and Research (PSR), 7(Special Issue on COVID-19), 2020, 1 – 11

Stem cell therapy in coronavirus disease 2019: current evidence and future potential. Rohit Shetty1, Ponnalagu Murugeswari2, Koushik Chakrabarty3, Chaitra Jayadev, Himanshu Matalia1, Arkasubhra Ghosh3, Debashish Das

Mehta P, McAuley DF, Brown M, et al. COVID-19: consider cytokine storm syndromes and immunosuppression. Lancet. 2020;395(10229):1033-1034. doi:10.1016/S0140-6736(20)30628-0

Khoury, M., Cuenca, J., Cruz, F. F., Figueroa, F. E., Rocco, P. R. M., & Weiss, D. J. (2020). Current Status of Cell-Based Therapies for Respiratory Virus Infections: Applicability to COVID-19. European Respiratory Journal, 2000858. doi:10.1183/13993003.00858-2020

Zakrzewski, W. et al., 2019. Stem cells: Past, present, and future. Stem Cell Research & Therapy, 10(1), pp.1–22.

Chouw, A. et al., 2021. Potency of mesenchymal stem cell and its secretome in treating COVID-19. Regenerative Engineering and Translational Medicine.

Zheng, G., Huang, L., Tong, H., Shu, Q., Hu, Y., Ge, M., Xu, J. (2014). Treatment of acute respiratory distress syndrome with allogeneic adipose-derived mesenchymal stem cells: a randomized, placebo-controlled pilot study. Respiratory Research, 15(1), 39. doi:10.1186/1465- 9921-15-39

Basiri, A. et al., 2021. Stem cell therapy potency in personalizing severe COVID-19 treatment. Stem Cell Reviews and Reports, 17(1), pp.193–213.

Pittenger, M. F., Discher, D. E., Péault, B. M., Phinney, D. G., Hare, J. M., & Caplan, A. I. (2019). Mesenchymal stem cell perspective: cell biology to clinical progress. NPJ Regenerative Medicine, 4(1), 22. doi:10.1038/ s41536-019-0083-6

Jiang, W., & Xu, J. (2020). Immune modulation by mesenchymal stem cells. Cell Proliferation, 53(1), e12712. doi:10.1111/cpr.12712

Xu, R., Feng, Z., Wang, Fu-Sheng. (2022). Mesenchymal stem cell treatment for COVID-19. eBioMedicine ; 77:103920. https://dor.org./10.1016/j.ebiom.2022.103920

Arabpour, E., Khoshdel, S., Tabatabaie, N., Akhgarzad, A., Zangiabadian, M., & Nasiri, M. J. (2021). Stem cells therapy for COVID-19: A systematic review and meta-analysis. Frontiers in Medicine, 8. https://doi.org/10.3389/fmed.2021.737590

Mahendiratta S, Bansal S, Sarma P, Kumar H, Choudhary G, Kumar S, et al. Stem cell therapy in COVID-19: pooled evidence from SARS-CoV-2, SARSCoV, MERS-CoV and ARDS: a systematic review. Biomed Pharmacother. (2021) 137:111300. doi: 10.1016/j.biopha.2021.111300

D. Rubin, U.S. FDA Clears Pluristem’s IND Application for Phase II COVID-19 Study, (2020). https://www.globenewswire.com/news-release/2020/05/08/ 2030212/0/en/U-S-FDA-Clears-Pluristem-s-IND-Application-for-Phase-IICOVID-19-Study.html. (Accessed 13 January 2022).

Mehta, P., McAuley, D. F., Brown, M., Sanchez, E., Tattersall, R. S., & Manson, J. J. (2020). COVID-19: Consider cytokine storm syndromes and immunosuppression. The Lancet, 395(10229), 1033- 1034.

Ye, Q., Wang, B., & Mao, J. (2020). The pathogenesis and treatment of the `Cytokine Storm’ in COVID-19. Journal of Infection, 80(6), 607-613.

Sidhu, K., (2020). The cytokine storm in COVID-19 patients amenable to stem cell treatment: A perspective. Stem Cell and Regenerative Medicine, 4(1), pp.1–11

Durand, N., Mallea, J. & Zubair, A.C., (2020). Insights into the use of mesenchymal stem cells in COVID-19 mediated acute respiratory failure. npj Regenerative Medicine, 5(1), pp.1–9.

Shu L, Niu C, Li R, Huang T, Wang Y, Ji N, et al. (2020). Treatment of severe COVID19 with human umbilical cord mesenchymal stem cells. Res Square. 11:1–11. doi: 10.21203/rs.3.rs-23696/v

Câmara, D.A. et al., (2021). A COVID-19 overview and potential applications of cell therapy. Biologics, 1(2), pp.177–188.

Leng, Z.; et al. (2020). Transplantation of ACE2- Mesenchymal Stem Cells Improves the Outcome of Patients with COVID-19 Pneumonia. Aging Dis.: 11, 216–228. [CrossRef] [PubMed]).

Arabpour, E. et al., (2021). Stem cells therapy for COVID-19: A systematic review and meta-analysis. Frontiers in Medicine, 8, pp.1–13.

Moll, G., Ankrum, J. A., Kamhieh-Milz, J., Bieback, K., Ringdén, O., Volk, H.-D., Reinke, P. (2019). Intravascular mesenchymal stromal/stem cell therapy product diversification: Time for new clinical guidelines. Trends in Molecular Medicine, 25(2), 149-163. doi:https://doi.org/10.1016/j.molmed.2018.12.006

Golchin, A., Seyedjafari, A., Ardeshirylajimi, A. (2020). Mesenchiymal Stem Cell Therapy for COVID-19 : Present or Future. Stem Cell Reviews and Reports. https://doi.org./10.1007/s12015-020-09973-w

Qu W, Wang Z, Hare JM, Bu G, Mallea JM, Pascual JM, Caplan AI, Kurtzberg J, Zubair AC, Kubrova E, Engelberg-Cook E, Nayfeh T, Shah VP, Hill JC, Wolf ME, Prokop LJ, Murad MH, Sanfilippo FP. Cell-based therapy to reduce mortality from COVID-19: Systematic review and meta-analysis of human studies on acute respiratory distress syndrome. Stem Cells Transl Med. 2020 Sep;9(9):1007-1022. doi: 10.1002/sctm.20-0146. Epub 2020 May 29. PMID: 32472653; PMCID: PMC7300743.

Downloads

Published

2022-05-31

Issue

Section

Articles